American Renal Associates (NYSE:ARA) Lowered to Buy at ValuEngine

Share on StockTwits

ValuEngine downgraded shares of American Renal Associates (NYSE:ARA) from a strong-buy rating to a buy rating in a research report sent to investors on Thursday, ValuEngine reports.

Separately, SunTrust Banks raised their target price on American Renal Associates from $7.00 to $12.00 and gave the stock a hold rating in a research note on Tuesday, September 10th. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. American Renal Associates has a consensus rating of Hold and a consensus target price of $11.25.

NYSE ARA traded down $0.13 during trading hours on Thursday, hitting $9.11. The company had a trading volume of 131,259 shares, compared to its average volume of 203,858. American Renal Associates has a 52 week low of $5.48 and a 52 week high of $17.31. The firm has a 50 day simple moving average of $7.43 and a 200 day simple moving average of $7.20. The company has a debt-to-equity ratio of 8.05, a quick ratio of 0.97 and a current ratio of 1.01. The firm has a market capitalization of $309.45 million, a price-to-earnings ratio of 13.96 and a beta of 2.09.

American Renal Associates (NYSE:ARA) last issued its earnings results on Tuesday, November 5th. The company reported $0.33 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.37. American Renal Associates had a positive return on equity of 23.16% and a negative net margin of 1.75%. The business had revenue of $211.43 million during the quarter, compared to the consensus estimate of $215.06 million. On average, research analysts forecast that American Renal Associates will post 0.03 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Adams Diversified Equity Fund Inc. boosted its stake in American Renal Associates by 24.7% in the 2nd quarter. Adams Diversified Equity Fund Inc. now owns 22,239 shares of the company’s stock worth $165,000 after purchasing an additional 4,400 shares during the period. JPMorgan Chase & Co. boosted its stake in American Renal Associates by 12.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 763,702 shares of the company’s stock worth $5,323,000 after purchasing an additional 84,361 shares during the period. Strs Ohio boosted its stake in American Renal Associates by 32.0% in the 2nd quarter. Strs Ohio now owns 79,200 shares of the company’s stock worth $589,000 after purchasing an additional 19,200 shares during the period. SG Americas Securities LLC bought a new stake in shares of American Renal Associates during the 2nd quarter valued at about $121,000. Finally, Stone Ridge Asset Management LLC bought a new stake in shares of American Renal Associates during the 2nd quarter valued at about $98,000. Institutional investors and hedge funds own 86.12% of the company’s stock.

About American Renal Associates

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Further Reading: Bond

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts Set $33.00 Target Price for SpringWorks Therapeutics
Analysts Set $33.00 Target Price for SpringWorks Therapeutics
Ardelyx Inc  Given Consensus Rating of “Hold” by Analysts
Ardelyx Inc Given Consensus Rating of “Hold” by Analysts
Western Midstream Partners LP  Receives $32.25 Consensus Price Target from Analysts
Western Midstream Partners LP Receives $32.25 Consensus Price Target from Analysts
SL Green Realty Corp  Receives $93.85 Average Price Target from Brokerages
SL Green Realty Corp Receives $93.85 Average Price Target from Brokerages
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics
Analysts Set SS&C Technologies Holdings, Inc.  Price Target at $65.91
Analysts Set SS&C Technologies Holdings, Inc. Price Target at $65.91


© 2006-2019 Ticker Report